PARP1 and neurofibroma: In the MDA Cancer Center study (Kivlin et al., 2016), 91 MPNSTs and 24 neurofibromas were analyzed: Overall, MPNST samples had higher levels of PARP1 expression than neurofibromas; no correlation with clinicopathological features was reported except with survival, which was nonsignificantly higher in MPNSTs with high vs low expression.